摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-{4-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-but-2-enyl}-4-iodo-benzamide | 675599-26-5

中文名称
——
中文别名
——
英文名称
N-{4-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-but-2-enyl}-4-iodo-benzamide
英文别名
N-[(E)-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]but-2-enyl]-4-iodobenzamide
N-{4-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-but-2-enyl}-4-iodo-benzamide化学式
CAS
675599-26-5
化学式
C21H22Cl2IN3O
mdl
——
分子量
530.236
InChiKey
QMKMSUCBVBINOY-OWOJBTEDSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    28
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    35.6
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-{4-[4-(2,3-dichloro-phenyl)-piperazin-1-yl]-but-2-enyl}-4-iodo-benzamide 生成 N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]-trans-but-2-enyl}-4-iodobenzamide oxalate
    参考文献:
    名称:
    Structurally rigid dopamine d3 receptor selective ligands and process for making them
    摘要:
    描述了一类结构刚性的多巴胺D3受体选择性配体家族。这个结构刚性的多巴胺D3受体选择性配体家族的公式如下:其中A是顺式或反式-CH═CH—,—C═C—或环己烷。B是顺式或反式-CH═CH—或缺失。R1代表一个可选择取代的苯基团,其中所述取代基选自以下组:氢、卤素、氨基、硝基、羟基、烷氧基、烷基、酰基和吡啶基,所述取代可以出现在邻位、间位或对位中的任何一个,或者R1代表一个杂环芳香环。首选的杂环芳香环是吲哚、喹喔啉、吡啶基、嘧啶基或咪唑基。R2和R3可以独立地是氢或卤素,或者R2单独可以是C1、C2或C3烷氧基,m为1或2,n为0、1或2。
    公开号:
    US20060106030A1
  • 作为产物:
    参考文献:
    名称:
    Novel Heterocyclic Trans Olefin Analogues of N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as Selective Probes with High Affinity for the Dopamine D3 Receptor
    摘要:
    Dopamine D3 receptor subtypes have been hypothesized to play a pivotal role in modulating the reinforcing and drug-seeking effects induced by cocaine. However, definitive pharmacological investigations have been hampered by the lack of highly D3 receptor selective compounds that can be used in vivo. To address this problem, the potent and D3-receptor-selective antagonist NGB 2904 (1, 9H-fluorene-2-carboxylic acid {4-[(2,3-dichlorophenyl)-piperazin-1-yl]-butyl} amide, K-i (hD3) = 2.0 nM, K-i (hD2(L)) = 112 nM, D2/D3 selectivity ratio of 56) was chosen as a lead structure for chemical modification in an attempt to reduce its high lipophilicity (c log D = 6.94) while optimizing D3 receptor binding affinity and D2/D3 selectivity. A series of >30 novel analogues were synthesized, and their binding affinities were evaluated in competition binding assays in HEK 293 cells transfected with either D2(L), D3, or D4 human dopamine receptors using the high affinity, selective D2-like receptor antagonist I-125-IABN. Structural diversity in the aryl amide end of the molecule Was found to have a major influence on (sub)nanomolar D3 receptor affinity and D2/D3 selectivity, which was optimized using a more rigid trans-butenyl linker between the aryl amide and the piperazine. Several analogues demonstrated superior D3 receptor binding affinities and selectivities as compared to the parent ligand. Compound 29 (N-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-trans-but-2-enyl}-4-pyridine- 2-yl-benzamide) displayed the most promising pharmacological profile (K-i (hD3) = 0.7 nM, K-i (hD2(L)) = 93.3 nM, D2/D3 selectivity ratio of 133). In addition, this ligand inhibited quinpirole stimulation of mitogenesis at human dopamine D3 receptors transfected into Chinese hamster ovary (CHO) cells, with an EC50 value of 3.0 nM. Compound 29 was a nearly 5 times more potent antagonist at the D3 receptor than 1 (EC50 = 14.4 nM). Moreover, a decrease in c log D value of similar to2 orders of magnitude was determined for this novel D3-receptor-preferring ligand, compared to 1. In summary, chemical modification of 1 has resulted in compounds with high affinity and selectivity for D3 receptors. The most promising candidate, compound 29, is currently being evaluated in animal models of cocaine abuse and will provide an important tool with which to elucidate the role of D3 receptors in drug reinforcement in vivo.
    DOI:
    10.1021/jm049465g
点击查看最新优质反应信息

文献信息

  • STRUCTURALLY RIGID DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND PROCESS FOR MAKING THEM
    申请人:Newman Amy
    公开号:US20100068138A1
    公开(公告)日:2010-03-18
    A family of structurally rigid dopamine D3 receptor selective ligands is described. The family of structurally rigid dopamine D3 receptor selective ligands has the formula wherein A is cis or trans —CH═CH—, —C═C—, or cyclohexyl. B is cis or trans —CH═CH— or absent. R1 represents an optionally substituted phenyl group, wherein said substituents are selected from the group consisting of: hydrogen, halogen, amino, nitro, hydroxyl, alkoxy, alkyl, acyl and pyridyl, and said substitution may occur at any of the ortho, meta, or para positions, or R1 represents a heteroaromatic ring. A preferred heteroaromatic ring is indole, quinoxoline, pyridyl, pyrimidyl, or imidazole. R2 and R3 may be independently hydrogen or a halogen, or R2 alone may be C1, C2, or C3 alkoxy, and m is 1 or 2, and n is 0, 1, or 2.
    描述了一类结构刚性的多巴胺D3受体选择性配体。该结构刚性的多巴胺D3受体选择性配体的化学式如下:其中A为顺式或反式-CH═CH—、—C═C—或环己基;B为顺式或反式-CH═CH—或不存在;R1代表一个可选取代的苯基,其中所述取代基选自羟基、卤素、氨基、硝基、烷氧基、烷基、酰基和吡啶基,所述取代可以出现在任何邻、间或对位,或者R1代表一个杂环芳烃环,其中优选的杂环芳烃环为吲哚、喹啉、吡啶基、嘧啶基或咪唑基。R2和R3可以独立地是氢或卤素,或者R2单独可以是C1、C2或C3的烷氧基,m为1或2,n为0、1或2。
  • US7605259B2
    申请人:——
    公开号:US7605259B2
    公开(公告)日:2009-10-20
  • US8119642B2
    申请人:——
    公开号:US8119642B2
    公开(公告)日:2012-02-21
  • Novel Heterocyclic Trans Olefin Analogues of <i>N</i>-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as Selective Probes with High Affinity for the Dopamine D3 Receptor
    作者:Peter Grundt、Erin E. Carlson、Jianjing Cao、Christina J. Bennett、Elizabeth McElveen、Michelle Taylor、Robert R. Luedtke、Amy Hauck Newman
    DOI:10.1021/jm049465g
    日期:2005.2.1
    Dopamine D3 receptor subtypes have been hypothesized to play a pivotal role in modulating the reinforcing and drug-seeking effects induced by cocaine. However, definitive pharmacological investigations have been hampered by the lack of highly D3 receptor selective compounds that can be used in vivo. To address this problem, the potent and D3-receptor-selective antagonist NGB 2904 (1, 9H-fluorene-2-carboxylic acid 4-[(2,3-dichlorophenyl)-piperazin-1-yl]-butyl} amide, K-i (hD3) = 2.0 nM, K-i (hD2(L)) = 112 nM, D2/D3 selectivity ratio of 56) was chosen as a lead structure for chemical modification in an attempt to reduce its high lipophilicity (c log D = 6.94) while optimizing D3 receptor binding affinity and D2/D3 selectivity. A series of >30 novel analogues were synthesized, and their binding affinities were evaluated in competition binding assays in HEK 293 cells transfected with either D2(L), D3, or D4 human dopamine receptors using the high affinity, selective D2-like receptor antagonist I-125-IABN. Structural diversity in the aryl amide end of the molecule Was found to have a major influence on (sub)nanomolar D3 receptor affinity and D2/D3 selectivity, which was optimized using a more rigid trans-butenyl linker between the aryl amide and the piperazine. Several analogues demonstrated superior D3 receptor binding affinities and selectivities as compared to the parent ligand. Compound 29 (N-4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-trans-but-2-enyl}-4-pyridine- 2-yl-benzamide) displayed the most promising pharmacological profile (K-i (hD3) = 0.7 nM, K-i (hD2(L)) = 93.3 nM, D2/D3 selectivity ratio of 133). In addition, this ligand inhibited quinpirole stimulation of mitogenesis at human dopamine D3 receptors transfected into Chinese hamster ovary (CHO) cells, with an EC50 value of 3.0 nM. Compound 29 was a nearly 5 times more potent antagonist at the D3 receptor than 1 (EC50 = 14.4 nM). Moreover, a decrease in c log D value of similar to2 orders of magnitude was determined for this novel D3-receptor-preferring ligand, compared to 1. In summary, chemical modification of 1 has resulted in compounds with high affinity and selectivity for D3 receptors. The most promising candidate, compound 29, is currently being evaluated in animal models of cocaine abuse and will provide an important tool with which to elucidate the role of D3 receptors in drug reinforcement in vivo.
  • Structurally rigid dopamine d3 receptor selective ligands and process for making them
    申请人:Newman Amy
    公开号:US20060106030A1
    公开(公告)日:2006-05-18
    A family of structurally rigid dopamine D3 receptor selective ligands is described. The family of structurally rigid dopamine D3 receptor selective ligands has the formula wherein A is cis or trans —CH═CH—, —C═C—, or cyclohexyl. B is cis or trans —CH═CH— or absent. R1 represents an optionally substituted phenyl group, wherein said substituents are selected from the group consisting of: hydrogen, halogen, amino, nitro, hydroxyl, alkoxy, alkyl, acyl and pyridyl, and said substitution may occur at any of the ortho, meta, or para positions, or R1 represents a heteroaromatic ring. A preferred heteroaromatic ring is indole, quinoxoline, pyridyl, pyrimidyl, or imidazole. R2 and R3 may be independently hydrogen or a halogen, or R2 alone may be C1, C2, or C3 alkoxy, and m is 1 or 2, and n is 0, 1, or 2.
    描述了一类结构刚性的多巴胺D3受体选择性配体家族。这个结构刚性的多巴胺D3受体选择性配体家族的公式如下:其中A是顺式或反式-CH═CH—,—C═C—或环己烷。B是顺式或反式-CH═CH—或缺失。R1代表一个可选择取代的苯基团,其中所述取代基选自以下组:氢、卤素、氨基、硝基、羟基、烷氧基、烷基、酰基和吡啶基,所述取代可以出现在邻位、间位或对位中的任何一个,或者R1代表一个杂环芳香环。首选的杂环芳香环是吲哚、喹喔啉、吡啶基、嘧啶基或咪唑基。R2和R3可以独立地是氢或卤素,或者R2单独可以是C1、C2或C3烷氧基,m为1或2,n为0、1或2。
查看更多